Hyclone Laboratories, Inc.

HyClone's origins began in 1967 when founder Dr. Rex Spendlove, then a professor at Utah State University, was studying a viral disease that was fatal to children, especially in developing countries. At that time, the quality of commercially available fetal bovine serum (FBS) was so poor that Dr. Spendlove was forced to develop his own methods to produce a high quality serum to meet his research needs. Recognizing a real need in the scientific community for high quality FBS, he founded a company that would meet that need.

Known throughout the industry as an innovator, HyClone pioneered many of the serum collection, filtration, and processing techniques currently used by cell culture product manufacturers. HyClone was the first large scale producer to collect fetal bovine blood using a patented closed-system collection method that resulted in serum with exceptionally low levels of endotoxin and hemoglobin. In addition, HyClone pioneered the use of highly retentive filtration techniques including triple 100 nm and 40 nm pore size rated filters, and was the first to establish a vertical integration of all serum collection and manufacturing processes.

From a small, but research focused beginning, HyClone has evolved into a world leader in manufacturing cell culture media, sera and bioprocess containment systems. Today, HyClone serves customers worldwide from its headquarters and primary manufacturing site in Logan, Utah, sites in the United Kingdom, Belgium, China, and New Zealand, and an extensive network of sales representatives and international distributors.